Login / Signup

Bulevirtide Combined with Pegylated Interferon for Chronic Hepatitis D.

Asselah TarikVladimir ChulanovPietro LamperticoHeiner WedemeyerAdrian Streinu-CercelVictor PânteaStefan LazarGheorghe PlacintaGeorge S GherlanPavel BogomolovTatyana StepanovaViacheslav MorozovVladimir SyutkinOlga SagalovaDmitry ManuilovRenee-Claude MercierLei YeBen L DaGrace CheeAudrey H LauAnu OsinusiMarc BourliereVlad RatziuStanislas PolMarie-Noëlle HilleretFabien ZoulimSamuel Didier
Published in: The New England journal of medicine (2024)
The combination of 10-mg bulevirtide plus peginterferon alfa-2a was superior to bulevirtide monotherapy with regard to an undetectable HDV RNA level at 24 weeks after the end of treatment. (Funded by Gilead Sciences; MYR 204 ClinicalTrials.gov number, NCT03852433.).
Keyphrases
  • combination therapy
  • dendritic cells
  • open label
  • clinical trial
  • nucleic acid